Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
羅氏集團成員基因泰克的Gazyva在狼瘡性腎炎研究中顯示出結果，可能延遲腎臟疾病。
Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response (CRR) at 76 weeks compared to those treated with standard therapy alone. Safety was in line with the well-characterized profile of Gazyva. No new safety signals were identified.
羅氏集團（SIX：RO，ROG，OTCQX: RHBY）的成員基因泰克今天宣佈了針對活動性狼瘡腎炎患者的Gazyva（obinutuzumab）的III期REGENCY研究的積極結果。在這項研究中，與單獨使用標準療法的患者相比，接受Gazyva加標準療法（mycophenolate mofetil和糖皮質激素）治療的患者在76周時獲得完全腎臟反應（CRR）的比例更高。安全性與Gazyva的鮮明特徵一致。沒有發現新的安全信號。
"Gazyva achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term...
首席醫學官兼全球產品開發主管Lev...
登入免費觀看全文
登入/註冊